Psilocybin shows efficacy to alleviate depression in human clinical trials for six or more
months after only one or two treatments. Another hallucinogenic drug, esketamine, has …

Depression is a widespread and devastating mental illness and the search for rapid-acting
antidepressants remains critical. There is now exciting evidence that the psychedelic …

Psychedelic drugs including psilocybin, N, N ʹ-dimethyltryptamine (DMT) and lysergic acid
diethylamide (LSD) are undergoing a renaissance as potentially useful drugs for various …

Psychedelic compounds have shown extraordinary potential in treating a wide range of
neuropsychiatric disorders. Psilocybin, for example, has now been shown in several clinical …

There is a serious need for novel therapies that treat individuals with depression, including
major depressive disorder (MDD) and treatment-resistant depression (TRD). An emerging …

The discovery of ketamine as a rapid-acting antidepressant spurred significant research to
understand its underlying mechanisms of action and to identify other novel compounds that …

Therapeutic deficiencies with monoaminergic antidepressants invites the need to identify
and develop novel rapid-acting antidepressants. Hitherto, ketamine and esketamine are …

Background: Evidence suggests that serotonergic psychedelics (eg psilocybin), have rapid-
acting and long-lasting antidepressant effects after a single dose. However, the mechanism …

Depression is a chronic and debilitating illness that interferes severely with many human
behaviors, and is the leading cause of disability in the world. There is data suggesting that …

Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use.
After the first English language report on LSD in 1950, psychedelics enjoyed a short-lived …